Latest 10-Q quarterly reports

Patriot Acquisition Corp. reports its Q2 2026 financial results, detailing its status as a SPAC with significant funds in trust and ongoing efforts to identify a business combination target.

Perimeter Acquisition Corp. I (PMTR) filed its Q2 2026 10-Q, detailing its financial status as a blank check company and its ongoing efforts to identify and complete a business combination.

Peraso Inc. reported a sharp 44% year-over-year revenue decline for Q2 2026, alongside continued operating losses, raising substantial doubt about its ability to continue as a going concern.

Range Capital Acquisition Corp. has extended its deadline to complete a business combination to March 23, 2027, following significant shareholder redemptions totaling nearly $99.5 million.

NSTS Bancorp, Inc. filed its Q2 2026 Form 10-Q, detailing financial performance, a proposed merger with Brookfield Bancshares, Inc., and the divestiture of its mortgage lending division.

Bain Capital GSS Investment Corp. reports on its financial condition for the quarter ended June 30, 2026, highlighting trust account balances and operational expenses as it seeks a business combination.

Republic Digital Acquisition Company reports financial results for the quarter ended June 30, 2026, highlighting income from trust investments and continued efforts towards a business combination.

Polaryx Therapeutics reported a net loss of $1.4 million for Q2 2026, with operating expenses increasing, though cash reserves grew due to financing activities, providing an estimated runway through Q1 2027.

KULR Technology Group, Inc. filed its Q2 2026 10-Q, revealing a significant decrease in revenue across product sales and digital asset mining, alongside a substantial net loss.

CV Sciences, Inc. (CVSI) filed its Q2 2026 10-Q, revealing a 17.5% year-over-year revenue decline and a widening net loss, raising going concern doubts.

Caribou Biosciences (CRBU) filed its Q2 2026 Form 10-Q, detailing ongoing clinical development for its CAR-T therapies, alongside financial results showing continued net losses and a reduction in operating expenses.

MariMed Inc. filed its Q2 2026 10-Q, showing a 6.1% revenue increase to $41.9 million but a widening net loss to $3.6 million, alongside a significant tax benefit from the reclassification of cannabis under federal law.

Heartflow, Inc. announced a 48% year-over-year revenue increase for the second quarter of 2026, driven by higher case volumes and the growing adoption of its Plaque Analysis product.

RenovoRx announces record quarterly revenue and commercial expansion, but faces ongoing challenges with Nasdaq listing compliance and continued net losses.

WidePoint Corporation reported an 11% year-over-year revenue increase to $78.6 million for the first six months of 2026, driven by managed services growth and a significant $3.1 billion DHS contract award, despite a pending protest.

Workhorse Group Inc. reported a net loss of $20.2 million for the quarter ended June 30, 2026, and faces substantial doubt regarding its ability to continue as a going concern.

Rhinebeck Bancorp, Inc. reported its quarterly results, highlighting the completion of a significant stock offering that substantially increased its capital and liquidity, alongside a slight decrease in net income and interest margins.

ImmuCell Corporation's Q2 2026 results show significant revenue and net income increases, driven by First Defense product sales and strategic operational adjustments.

Silo Pharma, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing research and development efforts in biopharmaceuticals and a cryptocurrency treasury strategy, alongside financial results showing continued net losses.

Scienture Holdings, Inc. (f/k/a TRxADE HEALTH, INC.) filed its Form 10-Q for the quarter ended June 30, 2026, detailing revenue growth from ARBLI commercialization and ongoing R&D efforts, while addressing liquidity concerns.

Silver Pegasus Acquisition Corp. reports its financial results for the quarter ended June 30, 2026, highlighting its ongoing search for a business combination and the significant cash reserves held in trust.

Elite Pharmaceuticals announced its second-quarter 2026 financial results, showing a decrease in revenue but a significant swing to net income, driven by favorable changes in derivative instrument valuations.

AmpliTech Group, Inc. reported a decrease in revenue and an increase in net loss for the second quarter of 2026, with significant growth in its distribution segment offset by declines in other areas.

ProMIS Neurosciences Inc. details positive interim clinical trial data for its lead Alzheimer's candidate, PMN310, and a significantly improved cash position following a substantial PIPE financing.

My Size Inc. reported a significant increase in net loss for Q2 2026, alongside ongoing concerns about its ability to continue as a going concern and maintain Nasdaq listing.

Sunshine Biopharma Inc. reported a decrease in revenue for Q2 2026 compared to the prior year, alongside continued net losses, but highlighted progress in its proprietary drug development pipeline and a strengthened cash position.

Matinas BioPharma's Q2 2026 report reveals severe financial distress, with substantial doubt about its going concern status, despite announcing significant strategic transactions including a business combination and asset sale.

Oragenics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses, a net loss of $2.5 million for the quarter, and continued concerns about its ability to continue as a going concern.

Vuzix Corporation reported a 14% decrease in total sales for Q2 2026 compared to the prior year, driven by lower product revenue, while research and development expenses increased by 20%.

ARS Pharmaceuticals' Q2 2026 filing shows a substantial increase in revenue driven by neffy sales, but also highlights significant increases in operating expenses and ongoing legal challenges.